Study #2024-0154
NRG-GU013: The phase III "High Five Trial" five fraction radiation for high-risk prostate cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Adenocarcinoma;Stage III Prostate Cancer AJCC v8;Stage IVA Prostate Cancer AJCC v8
Study phase:
Phase III
Physician name:
Karen Hoffman
Department:
Radiation Oncology
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.